PMID- 17311552
OWN - NLM
STAT- MEDLINE
DA  - 20070221
DCOM- 20070314
PUBM- Print
IS  - 1873-4316 (Electronic)
VI  - 8
IP  - 1
DP  - 2007 Feb
TI  - Development of tissue engineered vascular grafts.
PG  - 43-50
AB  - Vascular bypass grafting is a commonly performed procedure for ischemic
      heart disease and peripheral vascular disease. However, approximately one
      in fourteen patients do not have suitable autologous arteries or veins
      available for grafting. Synthetic vascular grafts were introduced in the
      1960s to overcome these problems, but while they perform adequately in
      high-flow, large-diameter vessel settings they are generally not suited to
      low-flow, small-diameter vessels. Tissue engineering is a relatively new
      discipline that offers the potential to create replacement structures from
      autologous cells and biodegradable polymer scaffolds. Because tissue
      engineering constructs contain living cells, they may have the potential
      to grow, self-repair, and self-remodel. Therefore, recently there has been
      much interest in the use of this technique to produce low-flow
      small-diameter arteries. The latest and most exciting developments in this
      area involve the use of multipotent stem cells as a cell source for tissue
      engineering of vascular grafts (both in vivo and in vitro).
AD  - Centre for Research in Vascular Biology, Department of Anatomy and
      Developmental Biology, School of Biomedical Sciences, Otto Hirschfeld
      Building, Room 513, University of Queensland, Brisbane, Queensland, 4072,
      Australia. g.campbell@uq.edu.au
FAU - Campbell, G R
AU  - Campbell GR
FAU - Campbell, J H
AU  - Campbell JH
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Curr Pharm Biotechnol
JT  - Current pharmaceutical biotechnology
JID - 100960530
SB  - IM
MH  - Animals
MH  - *Bioprosthesis
MH  - *Blood Vessel Prosthesis
MH  - Cell Culture Techniques/instrumentation/methods
MH  - Cell Proliferation
MH  - Endothelial Cells/*cytology/*physiology
MH  - Humans
MH  - Stem Cell Transplantation/methods
MH  - Stem Cells/*cytology/*physiology
MH  - Tissue Engineering/instrumentation/*methods
RF  - 107
EDAT- 2007/02/22 09:00
MHDA- 2007/03/16 09:00
PST - ppublish
SO  - Curr Pharm Biotechnol. 2007 Feb;8(1):43-50.

PMID- 17237555
OWN - NLM
STAT- MEDLINE
DA  - 20070122
DCOM- 20070316
PUBM- Print
IS  - 1550-8943 (Print)
VI  - 2
IP  - 2
DP  - 2006
TI  - Cord-blood mesenchymal stem cells and tissue engineering.
PG  - 163-8
AB  - Institute of Reconstructive Plastic Surgery, Laboratory of Vascular Tissue
      Engineering and Microvascular Research, New York University, New York, NY
      and Long Island Plastic Surgical Group, Garden City, NY Cord-blood-derived
      stem cells have proven clinically useful for numerous disease states, as
      have mesenchymal stem cells (MSCs) derived from bone marrow and adipose
      tissue. The recent identification of MSCs in cord-blood heralds cord-blood
      as an untapped resource for nonhematopoietic stem cell-based therapeutic
      strategies for the replacement of injured or diseased connective tissue.
      This review discusses the potential for tissue engineering applications of
      MSCs, highlighting the development of vascularized tissue engineering
      constructs using microvascular free flaps as a novel tissue engineering
      strategy.
AD  - Institute of Reconstructive Plastic Surgery, Laboratory of Vascular Tissue
      Engineering and Microvascular Research, New York University, New York, NY,
      USA. cetrulo4@hotmail.com
FAU - Cetrulo, Curtis L Jr
AU  - Cetrulo CL Jr
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Stem Cell Rev
JT  - Stem cell reviews
JID - 101255952
SB  - IM
MH  - Animals
MH  - Cell Lineage
MH  - Fetal Blood/*cytology
MH  - Humans
MH  - Mesenchymal Stem Cells/*cytology
MH  - Neovascularization, Physiologic
MH  - Tissue Engineering/*methods/trends
RF  - 55
EDAT- 2007/01/24 09:00
MHDA- 2007/03/17 09:00
PHST- 1999/11/30 [received]
PHST- 1999/11/30 [revised]
PHST- 1999/11/30 [accepted]
AID - SCR:2:2:163 [pii]
PST - ppublish
SO  - Stem Cell Rev. 2006;2(2):163-8.

PMID- 17237546
OWN - NLM
STAT- MEDLINE
DA  - 20070122
DCOM- 20070316
PUBM- Print
IS  - 1550-8943 (Print)
VI  - 2
IP  - 2
DP  - 2006
TI  - Umbilical cord cells as a source of cardiovascular tissue engineering.
PG  - 87-92
AB  - There is increasing scientific evidence that human umbilical cord cells
      are a valuable source of adult stem cells that can be used for various
      implications including regenerative medicine and tissue engineering. The
      review describes the role of progenitor cells (mesenchymal, endothelial,
      prenatal) for the use in cardiovascular tissue engineering, i.e., the
      formation of large vessels and heart valves from umbilical cord cells.
      Currently used replacements in cardiovascular surgery are made of foreign
      materials with well known drawbacks such as thrombo-embolic complications,
      infection, loss of functional and biological properties, and others.
      Especially in the field of replacements in congenital cardiac defects,
      there would be a need of materials which have the advantage of optimal
      biological and mechanical properties. In the case of human umbilical cord
      cells, autologous cells can be used by minimally invasive procedures. The
      cells have excellent growth capacities and form a neo-matrix with
      excellent mechanical properties. For optimal growth and modeling,
      scaffolds are required with high biocompatibility and biodegradability,
      which allow cell attachment, ingrowth, and organization. Nutrients and
      waste must be easily transported and cells should be in entire contact
      with host's body. Finally, regenerated materials can be fully incorporated
      and the scaffold is completely replaced. Besides these cell and scaffold
      requirements, feto-maternal conditions and risk factors concerning
      deriving stem cells are of major interest. There are still many open
      questions concerning whether and how maternal conditions such as infection
      (viral or bacterial) or gestational age of the newborn influence stem cell
      harvesting and quality. If these cells will be used for the construction
      of replacement materials, it is clear that very strict criteria and
      protocols be introduced enabling the promising step from isolated cells to
      a therapeutic device such as a new heart valve. It is hoped that it will
      be only a question of time until human umbilical cord cells will be used
      frequently as the source of cardiovascular tissues among others in the
      clinical setting of treating congenital heart defects.
AD  - Feto-Maternal Haematology Research Group, Obstetric Research, University
      Hospital Zurich. Christian.breymann@usz.ch
FAU - Breymann, Christian
AU  - Breymann C
FAU - Schmidt, Dorthe
AU  - Schmidt D
FAU - Hoerstrup, S P
AU  - Hoerstrup SP
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Stem Cell Rev
JT  - Stem cell reviews
JID - 101255952
SB  - IM
MH  - Animals
MH  - Cardiovascular Diseases/therapy
MH  - Cardiovascular System/*cytology
MH  - Humans
MH  - Saphenous Vein/cytology
MH  - Tissue Engineering/*methods
MH  - Tissue Therapy
MH  - Umbilical Cord/*cytology
RF  - 16
EDAT- 2007/01/24 09:00
MHDA- 2007/03/17 09:00
PHST- 1999/11/30 [received]
PHST- 1999/11/30 [revised]
PHST- 1999/11/30 [accepted]
AID - SCR:2:2:87 [pii]
PST - ppublish
SO  - Stem Cell Rev. 2006;2(2):87-92.

PMID- 17227284
OWN - NLM
STAT- MEDLINE
DA  - 20070117
DCOM- 20070228
LR  - 20070321
PUBM- Print
IS  - 1470-8744 (Electronic)
VI  - 46
IP  - Pt 2
DP  - 2007 Feb
TI  - Biomaterials and scaffold design: key to tissue-engineering cartilage.
PG  - 73-84
AB  - Cartilage remains one of the most challenging tissues to reconstruct or
      replace, owing to its complex geometry in facial structures and mechanical
      strength at articular surfaces in joints. This non-vascular tissue has
      poor replicative capacity and damage results in its functionally inferior
      repair tissue, fibrocartilage. This has led to a drive for advancements in
      tissue engineering. The variety of polymers and fabrication techniques
      available continues to expand. Pore size, porosity, biocompatibility,
      shape specificity, integration with native tissue, degradation tailored to
      rate of neocartilage formation and cost efficiency are important factors
      which need consideration in the development of a scaffold. The present
      review considers the current polymers and fabrication methodologies used
      in scaffold engineering for cartilage and postulates whether we are closer
      to developing the ideal scaffold for clinical application.
AD  - Biomaterials and Tissue Engineering Centre, University Department of
      Surgery, University College London, Royal Free and University College
      Medical School, University College London, Rowland Hill Street, London NW3
      2PF, UK.
FAU - Raghunath, Joanne
AU  - Raghunath J
FAU - Rollo, John
AU  - Rollo J
FAU - Sales, Kevin M
AU  - Sales KM
FAU - Butler, Peter E
AU  - Butler PE
FAU - Seifalian, Alexander M
AU  - Seifalian AM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Biotechnol Appl Biochem
JT  - Biotechnology and applied biochemistry
JID - 8609465
RN  - 0 (Biocompatible Materials)
SB  - IM
MH  - Animals
MH  - Biocompatible Materials/*chemistry
MH  - Biomimetic Materials/*chemistry
MH  - Cartilage/*cytology/*growth & development
MH  - Cell Culture Techniques/*methods
MH  - Cell Proliferation
MH  - Chondrocytes/cytology/physiology
MH  - Extracellular Matrix/*chemistry
MH  - Humans
MH  - Tissue Engineering/*methods
RF  - 110
EDAT- 2007/01/18 09:00
MHDA- 2007/03/01 09:00
AID - BA20060134 [pii]
AID - 10.1042/BA20060134 [doi]
PST - ppublish
SO  - Biotechnol Appl Biochem. 2007 Feb;46(Pt 2):73-84.

PMID- 17195462
OWN - NLM
STAT- MEDLINE
DA  - 20070101
DCOM- 20070130
PUBM- Print
IS  - 0724-6145 (Print)
VI  - 103
DP  - 2007
TI  - Perfusion effects and hydrodynamics.
PG  - 75-156
AB  - Biological processes within living systems are significantly influenced by
      the motion of the liquids and gases to which those tissues are exposed.
      Accordingly, tissue engineers must not only understand hydrodynamic
      phenomena, but also appreciate the vital role of those phenomena in
      cellular and physiologic processes both in vitro and in vivo. In
      particular, understanding the fundamental principles of fluid flow
      underlying perfusion effects in the organ-level internal environment and
      their relation to the cellular microenvironment is essential to
      successfully mimicking tissue behavior. In this work, the major principles
      of hemodynamic flow and transport are summarized, to provide readers with
      a physical understanding of these important issues. In particular, since
      quantifying hemodynamic events through experiments can require expensive
      and invasive techniques, the benefits that can be derived from the use of
      computational fluid dynamics (CFD) packages and neural networking (NN)
      models are stressed. A capstone illustration based on analysis of the
      hemodynamics of aortic aneurysms is presented as a representative example
      of this approach, to stress the importance of tissue responses to
      flow-induced events.
AD  - Department of Chemical Engineering, 102 Gleeson Hall, Oregon State
      University, Corvallis, OR 97331, USA. peattie@engr.orst.edu
FAU - Peattie, Robert A
AU  - Peattie RA
FAU - Fisher, Robert J
AU  - Fisher RJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Adv Biochem Eng Biotechnol
JT  - Advances in biochemical engineering/biotechnology
JID - 8307733
SB  - IM
MH  - Animals
MH  - Blood Flow Velocity/*physiology
MH  - Blood Vessels/*physiology
MH  - *Cell Physiology
MH  - Computer Simulation
MH  - Humans
MH  - *Models, Cardiovascular
MH  - Perfusion/instrumentation/*methods
MH  - Pulsatile Flow/physiology
MH  - Tissue Engineering/instrumentation/*methods
RF  - 104
EDAT- 2007/01/02 09:00
MHDA- 2007/01/31 09:00
PST - ppublish
SO  - Adv Biochem Eng Biotechnol. 2007;103:75-156.

PMID- 17173502
OWN - NLM
STAT- MEDLINE
DA  - 20061218
DCOM- 20070130
PUBM- Print
IS  - 1744-8344 (Electronic)
VI  - 4
IP  - 6
DP  - 2006 Nov
TI  - In search of a pediatric cardiac surgeon's 'Holy Grail': the ideal
      pulmonary conduit.
PG  - 861-70
AB  - The limited lifespan of all currently available conduits leads to repeat
      operations and interventional procedures in many children. Each
      reoperation entails considerable risk to life, expenditure and compromised
      quality of life as the conduit degenerates. The ideal conduit should be
      available freely, inexpensive, require no anticoagulation, be resistant to
      infection, free from thromboembolism, have no gradients or regurgitation
      and have unlimited durability. This review explores various options as
      surgeons and researchers endeavor to develop the ideal conduit--which will
      fulfill all of the above-mentioned criteria. Various currently available
      conduits are analyzed. Special emphasis is given to tissue-engineered
      valves and percutaneous valve implantations.
AD  - Apollo Hospital, Department of Cardiothoracic Surgery, 21 Greams Lane, Off
      Greams Road, Chennai-600006, India. nev_sheeba@yahoo.com
FAU - Solomon, Neville A G
AU  - Solomon NA
FAU - Pranav, Subaraya K
AU  - Pranav SK
FAU - Jain, Kailash A
AU  - Jain KA
FAU - Kumar, Madhan
AU  - Kumar M
FAU - Kulkarni, Chandrasekhar B
AU  - Kulkarni CB
FAU - Akbari, Jayesh
AU  - Akbari J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
SB  - IM
MH  - Animals
MH  - Bioprosthesis
MH  - Child
MH  - Heart Defects, Congenital/*surgery
MH  - Heart Valve Diseases/congenital/*surgery
MH  - *Heart Valve Prosthesis
MH  - Heart Valve Prosthesis Implantation/*methods
MH  - Heart Ventricles
MH  - Humans
MH  - Pulmonary Artery
MH  - Surgical Procedures, Minimally Invasive
MH  - Tissue Engineering
RF  - 56
EDAT- 2006/12/19 09:00
MHDA- 2007/01/31 09:00
AID - 10.1586/14779072.4.6.861 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2006 Nov;4(6):861-70.

PMID- 17150154
OWN - NLM
STAT- In-Process
DA  - 20061207
PUBM- Print
IS  - 1708-5381 (Print)
VI  - 14
IP  - 6
DP  - 2006 Nov-Dec
TI  - Development of a tissue-engineered bypass graft seeded with stem cells.
PG  - 338-42
AB  - The gold standard conduit for bypass of diseased small-diameter arteries
      remains autologous vascular tissue. In the absence of such tissue,
      patients are offered bypass with prosthetic material, with far less
      durable results. Vascular tissue engineering, the creation of a vascular
      conduit by seeding a tubular scaffold with various cells, may offer an
      alternative approach to this difficult situation. Herein we review some of
      the significant challenges that remain in designing an ideal vascular
      conduit and outline potential solutions offered by a graft created by
      seeding natural vascular tissue (decellularized vein allograft) with
      readily available autologous cells (adipose-derived stem cells).
AD  - Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA.
FAU - DiMuzio, Paul
AU  - DiMuzio P
FAU - Fischer, Lauren
AU  - Fischer L
FAU - McIlhenny, Stephen
AU  - McIlhenny S
FAU - DiMatteo, Christopher
AU  - DiMatteo C
FAU - Golesorhki, Negar
AU  - Golesorhki N
FAU - Grabo, Daniel
AU  - Grabo D
FAU - Tarola, Nicholas
AU  - Tarola N
FAU - Mericli, Alexander
AU  - Mericli A
FAU - Shapiro, Irving
AU  - Shapiro I
FAU - Tulenko, Thomas
AU  - Tulenko T
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - Canada
TA  - Vascular
JT  - Vascular
JID - 101196722
SB  - IM
EDAT- 2006/12/08 09:00
MHDA- 2006/12/08 09:00
PST - ppublish
SO  - Vascular. 2006 Nov-Dec;14(6):338-42.

PMID- 16918275
OWN - NLM
STAT- MEDLINE
DA  - 20060821
DCOM- 20061006
PUBM- Print
IS  - 1744-8344 (Electronic)
VI  - 4
IP  - 4
DP  - 2006 Jul
TI  - Surgical treatment of coronary multivessel disease.
PG  - 569-81
AB  - Coronary artery bypass grafting has had a significant impact on the
      treatment of angina, and has been the 'gold standard' since 1969. Its use
      and efficacy has been increased by revascularization in cardiac arrest and
      the use of the internal mammary artery. In parallel, catheter techniques
      have evolved by means of balloon dilatation and additional stenting. This
      has effected the referral to surgery despite the development of new
      arterialization techniques and minimally invasive surgery. As competing
      techniques, an acceptable equilibrium between surgery and stenting will be
      found within the next years.
AD  - University Hopsital for Cardiac Surgery Salzburg, Mullner Hauptstrasse 48,
      5020 Salzburg, Austria. o.stanger@salk.at
FAU - Stanger, Olaf
AU  - Stanger O
FAU - Unger, Felix
AU  - Unger F
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
SB  - IM
MH  - Angioplasty, Transluminal, Percutaneous Coronary
MH  - Clinical Competence
MH  - Coronary Artery Bypass, Off-Pump
MH  - Coronary Disease/physiopathology/*surgery
MH  - Coronary Vessels/surgery
MH  - Endarterectomy/methods
MH  - Endoscopy
MH  - Humans
MH  - Internal Mammary-Coronary Artery Anastomosis
MH  - *Myocardial Revascularization/methods
MH  - Radial Artery/transplantation
MH  - Robotics
MH  - Surgical Procedures, Minimally Invasive
MH  - Tissue Engineering
MH  - Tissue and Organ Harvesting/methods
MH  - Vascular Patency
MH  - Wound Healing
RF  - 155
EDAT- 2006/08/22 09:00
MHDA- 2006/10/07 09:00
AID - 10.1586/14779072.4.4.569 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2006 Jul;4(4):569-81.

